Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • April 27, 2025

Jaiswal V, Hanif M, Mashkoor Y, Prasad T, Fonarow GC. Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2025 Apr 14;4(5):101696. doi: 10.1016/j.jacadv.2025.101696. Epub ahead of print. PMID: 40286362.

Tags: Cardiology/Epi, Publications

Nuclear mechanotransduction: tools for mechanical perturbation and chromatin characterization

Soto J, Origer N, Wu Y, Cardenas Benitez B, Massad R, Rahgoshay D, Lee A, Downing T, Li S. Nuclear mechanotransduction: tools for mechanical perturbation[...]

Cannabis Is Associated With Potentially Proatherogenic Inflammation in Youth

Kelesidis T, Fotooh Abadi L, Lama Tamang P, Hampilos K, Fong R, Sanchez J, Ruedisueli I, Gornbein J, Cooper ZD, Middlekauff HR. Cannabis Is Associated[...]

Clinical outcomes among individuals with systemic inflammation following myocardial infarction: Insights from the veterans affairs healthcare system

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron DJ, Nallamshetty S, Din N, Fan M, Khachatourian K, Skaar JR, Tonnu-Mihara I. Clinical outcomes among[...]